MMP-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human 72 kDa type IV collagenase (MMP-2, UniProt P08253) expressed in HEK293 cells. Suited for gelatinase activity assays, inhibitor IC50 determinations, and antibody validation as a positive control standard.
Expression system
HEK293
Cat. #
REC-MMP2

In stock

SKU
REC-MMP2
$498.00

Target Overview

MMP-2 (Matrix metalloproteinase-2; UniProt P08253) is a 660-amino-acid secreted zinc-dependent endopeptidase classified under EC 3.4.24.24. It is the prototypic gelatinase of the MMP family, characterised by a hemopexin-like domain and three fibronectin type-II repeats that direct binding to gelatin and collagen substrates prior to catalysis. This recombinant is produced in HEK293 mammalian cells, an expression system that supports the post-translational folding and disulfide-bond formation required for proper hemopexin-domain architecture and catalytic competence — attributes that are difficult to replicate in prokaryotic systems. The protein is secreted as a latent zymogen; the prodomain must be removed (autocatalytically or via APMA activation in vitro) to yield the catalytically active form. Researchers should confirm activation status for their specific assay format. Once active, this recombinant cleaves fluorogenic gelatin-derived peptide substrates (e.g., Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) in standard kinetic assays and degrades reconstituted type IV collagen and gelatin in gel-based zymography. The HEK293-expressed protein carries human-compatible glycosylation patterns relevant to studies examining glycan-dependent interactions with tissue inhibitors of metalloproteinases (TIMPs) and cell-surface activators such as MMP-14. Sequence coverage spans full-length residues 1–660 of the canonical human sequence. Researchers using this recombinant as an antibody validation standard can pair it directly with the matched Triple Point Biologics antibody (SKU: RP-MMP2), which has been validated for Western blot against human MMP-2, with predicted cross-reactivity to mouse, rat, and primate orthologues.

Background

MMP-2 (72 kDa type IV collagenase; Gelatinase A) is a ubiquitously expressed matrix metalloproteinase with a broad substrate repertoire spanning extracellular matrix (ECM) components and non-matrix signalling proteins. Its canonical substrates include type IV, V, and VII collagens, gelatin, fibronectin, and laminin, positioning it as a central effector of basement membrane remodelling. Beyond ECM turnover, published studies have described MMP-2-mediated cleavage of big endothelial 1 and β-type CGRP, with consequences for vascular tone, and cleavage of GSK3β in in-vitro systems, implicating it in cardiomyocyte stress-response pathways. In basic vascular biology research, MMP-2 has been studied in the context of angiogenesis, atherosclerotic plaque instability, and arterial remodelling. Its activation cascade — relying on cell-surface complex formation with MMP-14 (MT1-MMP) and TIMP-2 — has made it a model system for studying metalloproteinase zymogen processing and pericellular proteolysis. MMP-2 has been investigated extensively as a research target in tumour biology. Published in-vitro and ex-vivo models have characterised its contribution to tumour cell invasion through basement membrane degradation. In a recent study of pancreatic cancer, Lee et al. (2026, PMID 42314234) described tumour microenvironment-activated nanoparticles engineered to respond to MMP activity in the peritumoral stroma — work that relied on MMP-2 cleavage specificity as a design parameter, illustrating how well-characterised recombinant enzyme preparations underpin mechanistic nanomedicine studies. In reproductive biology, MMP-2 activity has been characterised in cervical and decidual tissue remodelling, and recent integrative modelling of preterm labour has included MMP family members among inflammatory and matrix-remodelling signatures (Hong et al., 2026, PMID 42327783). MMP-2 has also appeared in network pharmacology analyses of ocular conditions such as myopia and dry eye disease, where it is identified among shared proteolytic targets at the scleral ECM level (Lin et al., 2026, PMID 42324572). For inhibitor research, recombinant MMP-2 is used to measure IC50 values for broad-spectrum and selective MMP inhibitors, including hydroxamates and macrocyclic scaffolds, in fluorescence-based kinetic assays. TIMP-1 and TIMP-2 inhibition constants are also routinely established against this enzyme. Triple Point Biologics has supplied proteinase and inhibitor research reagents since 1994, and this recombinant is produced to the same lot-consistency standards applied across the TPB proteinase portfolio.

Applications

  • Gelatinase activity assay using fluorogenic peptide substrates (e.g., Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) with kinetic readout
  • Inhibitor IC50 determination for hydroxamate, carboxylate, or macrocyclic MMP inhibitor scaffolds
  • Gelatin zymography positive control to confirm active-form migration at ~62 kDa and pro-form at ~72 kDa
  • Antibody validation positive control on Western blot — pair with matched TPB antibody RP-MMP2
  • TIMP-2 and TIMP-1 binding and inhibition constant (Ki) measurement by fluorescence or SPR
  • Type IV collagen and gelatin substrate degradation assay for extracellular matrix remodelling studies
  • MMP-14/TIMP-2-dependent zymogen activation reconstitution assay in cell-free systems
  • Substrate specificity profiling and non-matrix cleavage site identification by mass spectrometry

References

  1. Lee H et al. Stealthy systemic circulation of spatially controlled tumor microenvironment-activated bioadhesive proteinic nanoparticles for pancreatic cancer chemotherapy. Biomaterials. 2026. doi:10.1016/j.biomaterials.2026.124384. PMID: 42314234.
  2. Hong S et al. Vaginal dysbiosis and inflammatory signatures in preterm labor: an integrated model for predicting preterm birth. Front Immunol. 2026. doi:10.3389/fimmu.2026.1809046. PMID: 42327783.
  3. Lin M et al. Network pharmacology and molecular dynamics simulations reveal shared mechanisms and myopia-specific targets of atropine in myopia and dry eye disease. Eye Vis (Lond). 2026. doi:10.1186/s40662-026-00493-1. PMID: 42324572.
  4. Tashireva LA et al. Spatial Analysis of FAP Gene Expression in Breast Cancer. Curr Cancer Drug Targets. 2026. doi:10.2174/0115680096433584260407101537. PMID: 42333558.
  5. de Melo DG et al. Strength training induces ABHD5-ATGL axis to counteract mesenteric fat accumulation in obese Swiss mice. Life Sci. 2026. doi:10.1016/j.lfs.2026.124546. PMID: 42335984.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight band should I expect for recombinant MMP-2 on SDS-PAGE or Western blot?

Under reducing SDS-PAGE conditions, the latent pro-form of MMP-2 (UniProt P08253) runs at approximately 72 kDa. Following APMA-mediated activation and prodomain removal, the active form migrates at roughly 62-66 kDa. If you are using this protein as a positive control with our matched rabbit polyclonal antibody RP-MMP2, expect a clean band in the 62-72 kDa range depending on your activation status. A faint doublet is occasionally observed and reflects partial autocatalytic processing during storage rather than degradation. Confirm activation status before interpreting band shifts as artifacts.

What is the difference between latent and active MMP-2 and how do I activate the recombinant in vitro?

This recombinant is produced and secreted as a latent zymogen; the N-terminal prodomain (approximately 10 kDa) maintains autoinhibition via a conserved cysteine-zinc interaction. To generate the active 62-66 kDa catalytic form in vitro, incubate with 1 mM p-aminophenylmercuric acetate (APMA) for 1-2 hours at 37°C in assay buffer. Confirm activation by loss of the prodomain band on SDS-PAGE or by measurable cleavage of a fluorogenic gelatin-derived peptide substrate. For experiments requiring constitutively active enzyme, pre-activate and re-aliquot; repeated APMA treatment is not recommended.

What substrates does recombinant MMP-2 cleave and which fluorogenic peptide should I use for activity assays?

MMP-2 (EC 3.4.24.24) cleaves denatured collagen (gelatin), native type IV and type V collagens, and laminin. For quantitative activity assays, the fluorogenic peptide Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (commonly abbreviated Mca-PLGL-Dpa) is widely used; cleavage between Gly and Leu dequenches the Mca fluorophore (Ex/Em 320/405 nm). A working substrate concentration of 10-20 µM in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2) is a practical starting point. Ensure the enzyme is fully APMA-activated before running kinetics to avoid underestimating Vmax.

What buffer conditions and calcium concentration are optimal for recombinant MMP-2 activity assays?

The storage buffer for this recombinant — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol — is also suitable as a base assay buffer; simply dilute to your working concentration and omit glycerol if it interferes with your readout. Calcium (5 mM CaCl2) is essential for catalytic competence; do not substitute or omit it. Zinc contamination from plastic-ware can inhibit activity, so use low-metal-binding tubes. Detergent concentrations above 0.01% Tween-20 are not recommended. Optimal pH range is 7.0-7.5; activity drops significantly below pH 6.5.

What starting enzyme concentration should I use for a recombinant MMP-2 inhibitor IC50 assay?

For fluorogenic peptide-based IC50 determinations, 1-5 nM active MMP-2 in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 is a standard starting range. Use the lowest enzyme concentration that gives a linear signal increase over the assay window (typically 30-60 minutes) while remaining clearly above your fluorescence detection floor. At concentrations above 10 nM, tight-binding inhibitors can violate the [I] >> [E] assumption necessary for classical IC50 analysis; apply the Morrison equation if Ki approaches enzyme concentration. Pre-activate with APMA and quench activation before adding inhibitor to avoid confounding effects.

Can I use recombinant MMP-2 as a Western blot positive control with the RP-MMP2 antibody?

Yes — REC-MMP2 was validated alongside RP-MMP2 specifically for this purpose. Load 20-50 ng of the recombinant per lane alongside your cell lysate or conditioned medium samples; this amount reliably produces a strong 62-72 kDa band under standard ECL conditions. RP-MMP2 is a rabbit polyclonal raised against MMP-2 and has been validated in our lab for Western blot. Because the recombinant and antibody originate from the same development program, band identity is unambiguous. See /anti-mmp-2-rabbit-polyclonal-antibody for recommended antibody dilutions and blocking conditions.

How much recombinant MMP-2 should I load to validate the RP-MMP2 antibody for a new Western blot protocol?

For initial antibody titration experiments using RP-MMP2, a two-point loading of 10 ng and 50 ng REC-MMP2 per lane provides a useful dynamic range. Run these alongside a lysate lane from an MMP-2-expressing cell line (e.g., HT-1080 conditioned medium is a commonly used endogenous source). This approach confirms antibody linearity and distinguishes the ~72 kDa pro-form from the ~62-66 kDa active form. If signal is too strong at 10 ng, step down to 2-5 ng. Purity is >95% by SDS-PAGE, so off-target bands from the recombinant lane are not expected.

How should I store and handle recombinant MMP-2 to preserve activity, and what is its shelf life?

Store at -20°C in single-use aliquots as supplied. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol) is formulated to maintain stability through a single freeze-thaw cycle; repeated freeze-thaw significantly reduces gelatinase activity. Shelf life is 12 months from receipt when stored correctly. On the bench, keep on ice and use within 4 hours. Avoid glass surfaces — adsorption losses are non-trivial at low concentrations (<10 nM). Dilute working stocks in assay buffer supplemented with 0.1% BSA (low-endotoxin grade) to minimize surface-binding losses.

Validation imagery coming soon

Western blot validation figures for REC-MMP2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →